TETRA_150.jpg
Tetra Biopharma Confirms Type B Meeting Date With FDA Regarding HCC011
April 06, 2020 08:00 ET | Tetra Bio-Pharma Inc
OTTAWA, April 06, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to...
TETRA_150.jpg
Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF
April 02, 2020 08:00 ET | Tetra Bio-Pharma Inc
Bioanalytical methods developed and validated for its clinical trials. Tetra initiates study to quantify phytocannabinoid metabolites and precursors and minor phytocannabinoids in human plasma. ...
TETRA_150.jpg
Tetra Bio-Pharma Announces Filing of Restated Financial Statements and MD&A
March 30, 2020 09:20 ET | Tetra Bio-Pharma Inc
OTTAWA, March 30, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX-V: TBP) (OTCQB: TBPMF), announced today it has filed an amended and restated management’s...
Tetra Biopharma Survey Validates Primary Endpoint of SERENITY© Clinical Trial
March 26, 2020 07:00 ET | Tetra Bio-Pharma Inc
OTTAWA, March 26, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced...
TETRA_150.jpg
Tetra Bio-Pharma Provides Management Update on COVID-19
March 23, 2020 08:00 ET | Tetra Bio-Pharma Inc
OTTAWA, March 23, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today would...
TETRA_150.jpg
Tetra Bio-Pharma Engages Alpha Bronze LLC as investor relations and public relations firm
March 06, 2020 08:00 ET | Tetra Bio-Pharma Inc
OTTAWA, March 06, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to...
TETRA_150.jpg
Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientific
February 27, 2020 08:00 ET | Tetra Bio-Pharma Inc
OTTAWA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to...
TETRA_150.jpg
Tetra Bio-Pharma Provides Additional Information on CAUMZ Following Type B Meeting with USA FDA
February 25, 2020 08:00 ET | Tetra Bio-Pharma Inc
CAUMZ targeting survival indications in advanced incurable cancer. Eligible for Fast Track designation and Accelerated Approval regulatory program.505(b)(2) NDA pathway provides significant cost...
TETRA_150.jpg
Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following Letter of Advice & Type B Meeting with USA FDA
February 24, 2020 08:00 ET | Tetra Bio-Pharma Inc
QIXLEEF global market is expanded to include noncancer pain indications.Scientific approach to quality control of QIXLEEF validated by FDA.  OTTAWA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Tetra...
TETRA_150.jpg
Tetra Bio-Pharma Initiates a Proof of Concept Clinical Trial for its Ophthalmic Drug in Dogs
February 20, 2020 08:00 ET | Tetra Bio-Pharma Inc
A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary setting Trial expected to be completed by April 30, 2020 OTTAWA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Tetra...